EnteroTarget

Founded in 2018, Enterotarget is a dynamic spin-out company from the University of Copenhagen. It began its journey based on an exclusive license to a patent application for a unique treatment of inflammatory bowel disease. This treatment incorporates insulin as the active pharmaceutical ingredient, which is directly applied to the intestinal wall for a safer, side-effect-free solution. The product under this innovation is provisionally named "Enterocalm". In the process the ET-Capsule was invented and the capsule technology is now emerging as additional  product line.

Since its establishment, Enterotarget has been diligently progressing its Enterocalm technology and constructing a compelling business proposition around this patent. By 2021, we have secured patent approvals in 15 European countries, and added the US to our licensed patent portfolio in 2022. A patent application is also currently pending in Canada. 

Our strategic business model for Enterocalm has been fortified by establishing a significant partnership with Bioton S.A. for delivery of the API, insulin.

EnteroCalm has completed the preclinical stage and is now in clinical development where safety has already been demonstrated.

The committed efforts of our R&D team and collaborators have led to a another breakthrough invention - a specifically designed enteric capsule called the ET-Shuttle. This innovation allows for the oral administration and efficient release of Enterocalm directly into the colon. 

Enterotarget's patent attorney, Høiberg,  identified this unique capsule design  as a promising candidate for patenting, and a patent application was filed in October 2023

Building on this success, we at Enterotarget have therefore chosen to expand our product portfolio by introducing a second product line for the ET-Shuttle. This new offering will serve as a precise delivery mechanism for other medications as well as dietary supplements and probiotics targeted for large bowel health and function.

As we grow, we are eagerly seeking partners in the dietary supplement and probiotics sectors. We offer opportunities for licensing the use of the ET-Shuttle technology, and welcome any parties interested in leveraging this innovation for products aimed at improving large bowel health and function.